JWH-184: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
Line 1: Line 1:
'''JWH-184''' is a synthetic cannabinoid from the naphthoylindole family. It acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a binding affinity of 9.0 nM at CB1 and 2.94 nM at CB2. JWH-184 is one of the cannabinoids identified in herbal incense blends, and is illegal in some countries.
{{DISPLAYTITLE:JWH-184}}


==Chemistry==
== Overview ==
JWH-184 is a member of the [[naphthoylindole]] family of synthetic cannabinoids. It is structurally related to other synthetic cannabinoids such as [[JWH-018]] and [[JWH-073]]. The compound is named after the initials of its creator, John W. Huffman, a professor of organic chemistry at Clemson University who first synthesized these compounds for research purposes.
[[File:JWH-184.png|thumb|right|Chemical structure of JWH-184]]
'''JWH-184''' is a synthetic [[cannabinoid]] that acts as a potent agonist at the [[cannabinoid receptor]]s. It is part of the [[naphthoylindole]] family of compounds, which are known for their ability to mimic the effects of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of [[cannabis]].


==Pharmacology==
== Chemical Properties ==
JWH-184 acts as a full [[agonist]] at both the CB1 and CB2 [[cannabinoid receptors]]. The CB1 receptor is primarily located in the brain, while the CB2 receptor is found mainly in the immune system. The binding affinity of JWH-184 at the CB1 receptor is 9.0 nM, and at the CB2 receptor is 2.94 nM. This makes it a potent cannabinoid, with effects similar to those of [[tetrahydrocannabinol]] (THC), the primary psychoactive component of cannabis.
JWH-184 has the chemical formula C24H23NO and a molecular weight of 341.45 g/mol. It is characterized by its naphthoylindole structure, which consists of a naphthalene ring linked to an indole moiety. This structure is crucial for its activity at cannabinoid receptors.


==Legal Status==
== Pharmacology ==
JWH-184 is considered a controlled substance in several countries due to its potential for abuse and the health risks associated with its use. In the United States, it is classified as a Schedule I controlled substance, making it illegal to manufacture, distribute, or possess without a license. Other countries, such as the United Kingdom and Canada, have also banned the substance.
JWH-184 functions as a full agonist at both the [[CB1 receptor|CB1]] and [[CB2 receptor|CB2]] cannabinoid receptors. These receptors are part of the [[endocannabinoid system]], which plays a role in regulating various physiological processes such as pain, mood, and appetite. The activation of these receptors by JWH-184 can lead to effects similar to those produced by natural cannabinoids.


==Health Risks==
== Legal Status ==
The health risks associated with JWH-184 use are not fully understood, as there is limited research on this specific compound. However, synthetic cannabinoids in general have been associated with a range of adverse effects, including anxiety, paranoia, hallucinations, and in severe cases, seizures and heart attacks. Long-term use can lead to addiction and withdrawal symptoms.
Due to its potential for abuse and lack of medical use, JWH-184, like many synthetic cannabinoids, is classified as a controlled substance in many jurisdictions. The legal status of JWH-184 can vary significantly between countries and regions.


==See Also==
== Synthesis ==
The synthesis of JWH-184 involves the condensation of a naphthoyl chloride with an indole derivative. This reaction typically requires the use of a base to facilitate the formation of the naphthoylindole structure. The synthesis of JWH-184 is similar to that of other compounds in the JWH series, named after the chemist [[John W. Huffman]], who first synthesized many of these compounds.
 
== Potential Risks and Effects ==
[[File:JWH-184.png|thumb|left|Another view of JWH-184's structure]]
The use of JWH-184, like other synthetic cannabinoids, can pose significant health risks. These compounds can produce unpredictable and sometimes severe effects, including [[tachycardia]], [[hypertension]], [[hallucinations]], and [[psychosis]]. The lack of regulation and quality control in the production of synthetic cannabinoids further increases the risk of adverse effects.
 
== Related Pages ==
* [[Synthetic cannabinoids]]
* [[Synthetic cannabinoids]]
* [[Cannabinoid receptor]]
* [[Cannabinoid receptor]]
* [[Endocannabinoid system]]
* [[John W. Huffman]]
* [[John W. Huffman]]


[[Category:Synthetic cannabinoids]]
[[Category:Synthetic cannabinoids]]
[[Category:Designer drugs]]
[[Category:Naphthoylindoles]]
{{Pharma-stub}}
{{Chem-stub}}

Latest revision as of 03:45, 13 February 2025


Overview[edit]

Chemical structure of JWH-184

JWH-184 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the naphthoylindole family of compounds, which are known for their ability to mimic the effects of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis.

Chemical Properties[edit]

JWH-184 has the chemical formula C24H23NO and a molecular weight of 341.45 g/mol. It is characterized by its naphthoylindole structure, which consists of a naphthalene ring linked to an indole moiety. This structure is crucial for its activity at cannabinoid receptors.

Pharmacology[edit]

JWH-184 functions as a full agonist at both the CB1 and CB2 cannabinoid receptors. These receptors are part of the endocannabinoid system, which plays a role in regulating various physiological processes such as pain, mood, and appetite. The activation of these receptors by JWH-184 can lead to effects similar to those produced by natural cannabinoids.

Legal Status[edit]

Due to its potential for abuse and lack of medical use, JWH-184, like many synthetic cannabinoids, is classified as a controlled substance in many jurisdictions. The legal status of JWH-184 can vary significantly between countries and regions.

Synthesis[edit]

The synthesis of JWH-184 involves the condensation of a naphthoyl chloride with an indole derivative. This reaction typically requires the use of a base to facilitate the formation of the naphthoylindole structure. The synthesis of JWH-184 is similar to that of other compounds in the JWH series, named after the chemist John W. Huffman, who first synthesized many of these compounds.

Potential Risks and Effects[edit]

Another view of JWH-184's structure

The use of JWH-184, like other synthetic cannabinoids, can pose significant health risks. These compounds can produce unpredictable and sometimes severe effects, including tachycardia, hypertension, hallucinations, and psychosis. The lack of regulation and quality control in the production of synthetic cannabinoids further increases the risk of adverse effects.

Related Pages[edit]